Format

Send to

Choose Destination
Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115. Epub 2016 May 9.

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.

Author information

1
Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain.
2
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
3
Hospital Regional Universitario, Málaga, Spain.
4
HGU Morales Meseguer, Murcia, Spain.
5
Hospital Clínico Universitario, Salamanca, Spain.
6
Hospital Clínico Universitario, Valencia, Spain.
7
Hospital Universitario Ramón y Cajal, Madrid, Spain.
8
ICO Badalona, Badalona, Spain.
9
Hospital Universitario La Fé, Valencia, Spain.
10
Complejo Hospitalario de Navarra, Pamplona, Spain.
11
Hospital Universitario Son Espases, Palma de Mallorca, Spain.
12
Hospital Universitario La Princesa, Madrid, Spain.

Abstract

Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and 26 days. Cumulative incidences of grades II-IV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P=0.015) and OS (86% vs 46%; P=0.044). Our findings further confirm prior reports using HAPLO-RIC in advanced HL in a multicenter approach employing an IV busulfan-based conditioning regimen.

PMID:
27159177
DOI:
10.1038/bmt.2016.115
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center